Learn about pediatric low-grade glioma symptoms, causes, diagnosis, and treatment. Understand risk factors and prevention to ...

Haigis and Sabatini are co-senior authors of the study. Gliomas derive from glia, cells that perform essential functions in sculpting and maintaining neural circuits. Scientists already knew that ...

BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today announced the clinical development plan to ...

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...

The firm has discussed positive Phase I results on BCB-276 with the FDA and plans to move it directly to a registrational trial by year-end.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Following a positive meeting with the FDA, BrainChild is getting ready to initiate a pivotal registration trial with its lead ...

Plixorafenib is under clinical development by Fore Biotherapeutics and currently in Phase II for Glioma. According to GlobalData, Phase II drugs for Glioma have a 23% phase transition success rate ...

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with ...